Androgen Receptor Expression in Breast Cancer: What Differences Between Primary Tumor and Metastases?

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Genomic studies have shown that the androgen receptor (AR) pathway plays an important role in some breast cancer subtypes. However few data are present on the concordance between AR expression in primary tumors and metastases. We investigated AR expression by using immunohistochemistry (IHC) in 164 primary tumors and 83 metastases, to explore its distribution in the different tumor subtypes and its concordance between the two sample types and according to sampling time. AR was more highly expressed in luminal A and B than HER2-positive and triple negative primary tumors. A similar distribution was found in metastases, and the concordance of AR expression between primary tumors and metastases was greater than 60%. No association between sampling time and AR expression was observed. We found a good concordance of AR expression between primary tumor and metastasis, but the variability remains high between the two types of specimens, regardless of the variation in sampling time. For this reason, if used for treatment decisions, AR evaluation should be repeated in each patient whenever a new biopsy is performed, as commonly done for the other breast cancer biomarkers.

Original languageEnglish
Pages (from-to)950-956
Number of pages7
JournalTranslational Oncology
Volume11
Issue number4
DOIs
Publication statusPublished - Aug 1 2018

Fingerprint

Androgen Receptors
Breast Neoplasms
Neoplasm Metastasis
Neoplasms
Tumor Biomarkers
Immunohistochemistry
Biopsy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

@article{05a597ad31254088b95094a995d7c4ba,
title = "Androgen Receptor Expression in Breast Cancer: What Differences Between Primary Tumor and Metastases?",
abstract = "Genomic studies have shown that the androgen receptor (AR) pathway plays an important role in some breast cancer subtypes. However few data are present on the concordance between AR expression in primary tumors and metastases. We investigated AR expression by using immunohistochemistry (IHC) in 164 primary tumors and 83 metastases, to explore its distribution in the different tumor subtypes and its concordance between the two sample types and according to sampling time. AR was more highly expressed in luminal A and B than HER2-positive and triple negative primary tumors. A similar distribution was found in metastases, and the concordance of AR expression between primary tumors and metastases was greater than 60{\%}. No association between sampling time and AR expression was observed. We found a good concordance of AR expression between primary tumor and metastasis, but the variability remains high between the two types of specimens, regardless of the variation in sampling time. For this reason, if used for treatment decisions, AR evaluation should be repeated in each patient whenever a new biopsy is performed, as commonly done for the other breast cancer biomarkers.",
author = "Giuseppe Bronte and Sara Bravaccini and Sara Ravaioli and Maurizio Puccetti and Emanuela Scarpi and Daniele Andreis and Tumedei, {Maria Maddalena} and Samanta Sarti and Lorenzo Cecconetto and Elisabetta Pietri and {De Simone}, Valeria and Roberta Maltoni and Massimiliano Bonaf{\`e} and Dino Amadori and Andrea Rocca",
year = "2018",
month = "8",
day = "1",
doi = "10.1016/j.tranon.2018.05.006",
language = "English",
volume = "11",
pages = "950--956",
journal = "Translational Oncology",
issn = "1936-5233",
publisher = "Neoplasia Press",
number = "4",

}

TY - JOUR

T1 - Androgen Receptor Expression in Breast Cancer

T2 - What Differences Between Primary Tumor and Metastases?

AU - Bronte, Giuseppe

AU - Bravaccini, Sara

AU - Ravaioli, Sara

AU - Puccetti, Maurizio

AU - Scarpi, Emanuela

AU - Andreis, Daniele

AU - Tumedei, Maria Maddalena

AU - Sarti, Samanta

AU - Cecconetto, Lorenzo

AU - Pietri, Elisabetta

AU - De Simone, Valeria

AU - Maltoni, Roberta

AU - Bonafè, Massimiliano

AU - Amadori, Dino

AU - Rocca, Andrea

PY - 2018/8/1

Y1 - 2018/8/1

N2 - Genomic studies have shown that the androgen receptor (AR) pathway plays an important role in some breast cancer subtypes. However few data are present on the concordance between AR expression in primary tumors and metastases. We investigated AR expression by using immunohistochemistry (IHC) in 164 primary tumors and 83 metastases, to explore its distribution in the different tumor subtypes and its concordance between the two sample types and according to sampling time. AR was more highly expressed in luminal A and B than HER2-positive and triple negative primary tumors. A similar distribution was found in metastases, and the concordance of AR expression between primary tumors and metastases was greater than 60%. No association between sampling time and AR expression was observed. We found a good concordance of AR expression between primary tumor and metastasis, but the variability remains high between the two types of specimens, regardless of the variation in sampling time. For this reason, if used for treatment decisions, AR evaluation should be repeated in each patient whenever a new biopsy is performed, as commonly done for the other breast cancer biomarkers.

AB - Genomic studies have shown that the androgen receptor (AR) pathway plays an important role in some breast cancer subtypes. However few data are present on the concordance between AR expression in primary tumors and metastases. We investigated AR expression by using immunohistochemistry (IHC) in 164 primary tumors and 83 metastases, to explore its distribution in the different tumor subtypes and its concordance between the two sample types and according to sampling time. AR was more highly expressed in luminal A and B than HER2-positive and triple negative primary tumors. A similar distribution was found in metastases, and the concordance of AR expression between primary tumors and metastases was greater than 60%. No association between sampling time and AR expression was observed. We found a good concordance of AR expression between primary tumor and metastasis, but the variability remains high between the two types of specimens, regardless of the variation in sampling time. For this reason, if used for treatment decisions, AR evaluation should be repeated in each patient whenever a new biopsy is performed, as commonly done for the other breast cancer biomarkers.

UR - http://www.scopus.com/inward/record.url?scp=85048198813&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048198813&partnerID=8YFLogxK

U2 - 10.1016/j.tranon.2018.05.006

DO - 10.1016/j.tranon.2018.05.006

M3 - Article

AN - SCOPUS:85048198813

VL - 11

SP - 950

EP - 956

JO - Translational Oncology

JF - Translational Oncology

SN - 1936-5233

IS - 4

ER -